December 21, 2018

Home

Welcome to MangoGen Pharma

 DEVELOPING TOMORROWS IDEAS TODAY

MangoGen Pharma is a privately-owned bio-engineering company with a mission to develop novel gene-delivering medical devices that improve human health. MangoGen, located in Laval, Quebec, Canada, and owns a novel patented platform technology that utilizes encapsulated genetically modified baculoviruses coated on to medical devices. On device deployment, the virus enters the local cells, delivers the human gene, and an active protein is expressed. MangoGen’s focus is a product pipeline that includes the development of the next generation of stents – a gene-delivering coronary stent, as well as a gene-delivering film-dressing to promote and accelerate wound healing (e.g. for diabetic foot ulcers), gene-delivering sutures and gene-delivering creams to prevent scar tissue formation.

Platform Product Pipeline

Gene-Delivering Coronary Stents

The next generation of coronary stent is a gene-delivering stent designed to rapidly repair the damaged inner lining of the blood vessel surrounding the stent.

Gene-Delivering Film-Dressings

There is a pressing need to develop new approaches to treat diabetic foot ulcers. MangoGen is developing a film-dressing that delivers a wound healing gene. 

Gene-Delivering Sutures​

Gene-delivering sutures designed to promote and accelerate wound healing and preventing scar tissue formation.

Gene-Delivering Creams/Gels

Gene-delivering sutures designed to promote and accelerate wound healing and preventing scar tissue formation.​